menu search

coherus to acquire surface oncology

– Surface acquisition and potential toripalimab approval will transform coherus into an I-O company w...

June 16, 2023, 11:01 am

This biotech is about to eat abbvie's market share, but is it a buy?

coherus Biosciences will soon likely commercialize a generic copy of Humira. Humira is AbbVie's largest...

June 16, 2023, 8:30 am

Surface oncology stock rallies on all-stock acquisition by coherus

Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by ...

June 16, 2023, 7:51 am

Abbvie, coherus agree to resolve dispute over humira biosimilar

coherus BioSciences Inc said on Thursday it had agreed to resolve a dispute over its plans to launch a ...

June 15, 2023, 7:10 am

Why abbvie and amgen are moving lower today

Today, coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. ...

June 1, 2023, 12:50 pm

coherus biosciences to launch humira biosimilar at $995 per carton

coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's blockbuster ar...

June 1, 2023, 9:24 am

Fda flags issues at coherus partner's china manufacturing site for cancer drug

coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) flagged thre...

May 31, 2023, 1:37 pm

Top 5 health care stocks that could blast off in may - coherus biosciences (nasdaq:chrs), intercept pharma (nasdaq:icpt)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies....

May 26, 2023, 8:56 am

coherus biosciences, inc. (chrs) q1 2023 earnings call transcript

coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Compan...

May 8, 2023, 9:40 pm

coherus biosciences to report first quarter 2023 financial results on may 8, 2023

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- coherus BioSciences, Inc. (“...

May 1, 2023, 4:07 pm

coherus biosciences, inc. (chrs) q4 2022 earnings call transcript

coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Comp...

March 6, 2023, 10:22 pm

coherus biosciences (chrs) reports q4 loss, misses revenue estimates

coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, f...

March 6, 2023, 6:49 pm

coherus biosciences to present at upcoming investor conferences in march

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- coherus BioSciences, Inc. (“...

March 1, 2023, 8:25 am

coherus biosciences to report fourth quarter and full year 2022 financial results on march 6, 2023

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- coherus BioSciences, Inc. (“...

February 28, 2023, 8:25 am

coherus biosciences announces new employment inducement grants

REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) — coherus BioSciences, Inc. (“...

February 3, 2023, 10:30 pm

coherus agrees to acquire exclusive u.s. commercial rights to eylea® biosimilar fyb203 from klinge biopharma

Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) �...

January 9, 2023, 1:20 pm

coherus: launch of humira biosimilar may boost stock

coherus BioSciences got its toripalimab launch delayed due to the Chinese pandemic restrictions. Howeve...

January 9, 2023, 8:00 am

coherus biosciences management to present at the 41st annual j.p. morgan healthcare conference

REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- coherus BioSciences, Inc. (“...

January 4, 2023, 7:01 am

coherus and junshi biosciences share update on the fda review of the biologics license application (bla) for toripalimab as treatment for recurrent or metastatic nasopharyngeal carcinoma (npc)

– FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA – – ...

December 24, 2022, 5:01 am

coherus biosciences, inc. (chrs) q3 2022 earnings call transcript

coherus BioSciences, Inc. (NASDAQ:CHRS ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET C...

November 8, 2022, 11:42 pm


Search within

Pages Search Results: